ANDA 91226, held by Mylan Pharms Inc. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 91226 (Atorvastatin Calcium), held by Mylan Pharms Inc, was first approved by FDA on May 29, 2012, with 11 approved supplements and 0 published complete response letters.
Atorvastatin calcium tablets are indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 29, 2012 | Original application | Approved |
| Atorvastatin CalciumEQ 10MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 20MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 40MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Dec 5, 2024 | Supplement 32Labeling · Standard review | Approved | None posted |
| Jul 11, 2023 | Supplement 30Labeling · Standard review | Approved | None posted |
| Jan 15, 2021 | Supplement 19Labeling · Standard review | Approved | None posted |
| Jan 15, 2021 | Supplement 18Labeling · Standard review | Approved | None posted |
| Jan 15, 2021 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jan 15, 2021 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jan 15, 2021 | Supplement 10Manufacturing | Approved | None posted |
| Nov 9, 2015 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 26, 2014 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 23, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 5, 2013 | Supplement 1Labeling · Standard review | Approved | |
| May 29, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters